abstract |
The present invention relates to the design of a personalized therapy for a subject with breast cancer based on the expression level of c-MAF and the subject's menopausal status. In some embodiments, personalized therapy comprises an agent to prevent or prevent bone degradation. In some embodiments, the agent to prevent or prevent bone breakdown is zoledronic acid. |